Citations

Clear

50 citation(s) found for "Soto, Alexandra".

Genome-wide association study of neuropathological features in Lewy body disease
Koga, Shunsuke , Soto‐Beasley, Alexandra I. , Ono, Daisuke , Wieczorek, Mikolaj A. , White, Launia J. , Watkins, Molly M. , Murray, Melissa E. , Kasanuki, Koji , McLean, Pamela J. , Uitti, Ryan J. , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Ertekin‐Taner, Nilüfer , Savica, Rodolfo , Graff‐Radford, Jonathan , Petersen, Ronald , Parisi, Joseph E., Reichard, R. Ross , Ferman, Tanis J. , Ross, Owen A. , Valentino, Rebecca R. , Koga, Shunsuke , Murray, Melissa E , Springer, Wolfdieter , Botha, Hugo , Ramanan, Vijay K , Kantarci, Kejal , Jack, Clifford R , Graff-Radford, Jonathan , Boeve, Brad , Dickson, Dennis W , Ross, Owen A , Ferman, Tanis J , Beasley, Alexandra I , McLean, Pamela J , Johnson, Patrick W. , Springer, Wolfdieter , Botha, Hugo , Ramanan, Vijay K. , Brás, José , Guerreiro, Rita , Graff, Caroline , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Heckman, Michael G.

Mayo Clinic

Brain | March 14, 2025 | Volume: 148 | Issue: 8 | Pages: 2785-2796

10.1093/brain/awaf105 | PMID 40091616 Get It

Abstract Studies assessing genetic associations with neuropathological features in Lewy body disease (LBD) have been limited to candidate gene investigations, and therefore, information is lacking regarding the genetic architecture of the neuropathology of LBD. In the current study, we examined a large series of neuropathologically confirmed LBD cases (n = 980 in the discovery series, n = 503 in the replication series) and performed genome-wide association studies of 11 different neuropathological outcome measures. The 11 neuropathological outcomes included Braak neurofibrillary tangle (NFT) stage, Thal amyloid phase, LBD subtype, Lewy body (LB) counts in five different brain regions, dorsolateral and ventromedial putaminal tyrosine hydroxylase immunoreactivity and neuronal loss in the ventrolateral part of the substantia nigra. Associations between variants and outcomes were assessed using regression models appropriate for the nature of the given neuropathological outcome and that were adjusted for age at death, sex and top principal components of genetic data. In the discovery series, APOE rs429358 (i.e. APOE ε4) was associated with a greater severity of each of Braak NFT stage [odds ratio (OR) = 3.07, P = 2.34 × 10−32], Thal amyloid phase (OR = 3.57, P = 3.28 × 10−29) and LBD subtype (OR = 1.78, P = 9.85 × 10−9), with similar findings observed in the independent replication series (Braak NFT stage, OR = 2.30, P = 2.70 × 10−11; Thal amyloid phase, OR = 3.17, P = 6.39 × 10−18; LBD subtype, OR = 2.68, P = 3.85 × 10−10). In the subgroup of cases with lower levels of Alzheimer's disease pathology (Braak NFT stage ≤ III and Thal amyloid phase ≤2), there was a strong association between APOE rs429358 and LBD subtype even when adjusting for Braak stage and Thal phase in the discovery series (n = 218, OR = 2.47, P = 0.007) and the replication series (n = 141, OR = 3.60, P = 0.006). Although additional genome-wide significant associations were identified in the discovery series between LINC01581/MCTP2 rs547411734 and lower middle frontal LB counts, between TLE3 rs3743309 and lower cingulate LB counts, and between GRIN2A/ATF7IP2 rs1097915 and lower parahippocampal LB counts, these findings were not observed in the replication series. Our results indicate that the APOE ε4 allele is the most prominent genetic determinant of severity of neuropathology in LBD. These findings represent a key step forward in our understanding of genetic drivers of neuropathological features in LBD. Future studies utilizing meta-analytical approaches will be important to more precisely assess other associations that were not quite genome-wide significant in the discovery series.
Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs
Jin, Yunjung , Li, Fuyao , Li, Zonghua , Ikezu, Tadafumi C. , O’Leary, Justin , Selvaraj, Manikandan , Zhu, Yiyang , Martens, Yuka A. , Koga, Shunsuke , Santhakumar, Hannah , Li, Yonghe , Lü, Wenyan, You, Yang , Lolo, Kiara , DeTure, Michael , Davis, Mary Dabney , McLean, Pamela J. , Ross, Owen A. , Kanekiyo, Takahisa , Zhao, Na , Beasley, Alexandra I , Davis, Mary D , McLean, Pamela J , Ross, Owen A , Kanekiyo, Takahisa , Ikezu, Tsuneya , Caulfield, Thomas R , Carr, Jonathan , Wszolek, Z.K. , Bu, Guojun , Dickson, Dennis W , Zhao, Na , Koga, Shunsuke , Li, Zonghua , Li, Fuyao , Yang, You , Soto‐Beasley, Alexandra I. , Ikezu, Tsuneya , Caulfield, Thomas R. , Carr, Jonathan , Wszołek, Zbigniew K. , Bu, Guojun , Dickson, Dennis W.

Mayo Clinic

Science Advances | September 11, 2024 | Volume: 10 | Issue: 37 | Pages: No page available

10.1126/sciadv.adk3700 | PMID 39259788 Get It

Aggregated α-synuclein (α-SYN) proteins, encoded by the SNCA gene, are hallmarks of Lewy body disease (LBD), affecting multiple brain regions. However, the specific mechanisms underlying α-SYN pathology in cortical neurons, crucial for LBD-associated dementia, remain unclear. Here, we recapitulated α-SYN pathologies in human induced pluripotent stem cells (iPSCs)–derived cortical organoids generated from patients with LBD with SNCA gene triplication. Single-cell RNA sequencing, combined with functional and molecular validation, identified synaptic and mitochondrial dysfunction in excitatory neurons exhibiting high expression of the SNCA gene, aligning with observations in the cortex of autopsy-confirmed LBD human brains. Furthermore, we screened 1280 Food and Drug Administration–approved drugs and identified four candidates (entacapone, tolcapone, phenazopyridine hydrochloride, and zalcitabine) that inhibited α-SYN seeding activity in real-time quaking-induced conversion assays with human brains, reduced α-SYN aggregation, and alleviated mitochondrial dysfunction in SNCA triplication organoids and excitatory neurons. Our findings establish human cortical LBD models and suggest potential therapeutic drugs targeting α-SYN aggregation for LBD.
Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment
Soto‐Piña, Alexandra Estela , Pulido-Alvarado, Caroline C., Dulski, Jarosław , Wszołek, Zbigniew K. , Magaña, Jonathan J. , Wszolek, Z.K. , Soto-Piña, Alexandra E., Dulski, Jaroslaw

Mayo Clinic

International Journal of Molecular Sciences | July 24, 2024 | Volume: 25 | Issue: 15 | Pages: 8074

10.3390/ijms25158074 | PMID 39125644 Get It

Spinocerebellar ataxia type 3 (SCA3) is the most common type of disease related to poly-glutamine (polyQ) repeats. Its hallmark pathology is related to the abnormal accumulation of ataxin 3 with a longer polyQ tract (polyQ-ATXN3). However, there are other mechanisms related to SCA3 progression that require identifying trait and state biomarkers for a more accurate diagnosis and prognosis. Moreover, the identification of potential pharmacodynamic targets and assessment of therapeutic efficacy necessitates valid biomarker profiles. The aim of this review was to identify potential trait and state biomarkers and their potential value in clinical trials. Our results show that, in SCA3, there are different fluid biomarkers involved in neurodegeneration, oxidative stress, metabolism, miRNA and novel genes. However, neurofilament light chain NfL and polyQ-ATXN3 stand out as the most prevalent in body fluids and SCA3 stages. A heterogeneity analysis of NfL revealed that it may be a valuable state biomarker, particularly when measured in plasma. Nonetheless, since it could be a more beneficial approach to tracking SCA3 progression and clinical trial efficacy, it is more convenient to perform a biomarker profile evaluation than to rely on only one.
Genetic risk variants for Parkinson’s disease (PD) and cognitive impairment in four clinical PD subtypes (S3.004)
Deutschländer, Angela , Soto, Alexandra I., Ossi, Maryam, Strongosky, Audrey , Uitti, Ryan J. , Gerpen, Jay Van, Konno, Takuya , Heckman, Michael G. , Gerpen, Jay A. van, Ross, Owen A. , Wszołek, Zbigniew K.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s3.004 Get It

Characterization of variants in genes associated with Parkinson’s disease and parkinsonism in the African American population using exome sequencing (P2.079)
Deutschländer, Angela , Soto, Alexandra I., Walton, Ronald L., Reddy, Joseph S. , Strongosky, Audrey , Carrasquillo, Minerva M. , LeDoux, Mark S. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Ross, Owen A. , Wszołek, Zbigniew K.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p2.079 Get It

Low Density Lipoprotein Receptor Related Protein-1 and 6 Gene Variants and Ischemic Stroke Risk (P6.279)
Soto‐Ortolaza, Alexandra I., Soto‐Beasley, Alexandra I. , Beasley, Alexandra I , Harriott, Andrea M. , Heckman, Michael G. , Rayaprolu, Sruti , Cole, John W. , Meschia, James F. , Ross, Owen A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p6.279 Get It

Association between glucocerebrosidase mutations and Parkinson’s disease in Ireland (S53.003)
McCarthy, Allan, Soto, Alexandra I., Walton, Ronald L., Magennis, Brian, Lynch, Timothy, Olszewska, Diana A. , McLaughlin, Russell L. , Hardiman, Orla , Ross, Owen A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s53.003 Get It

PTPA variants are rare in early-onset and familial Parkinson’s disease
Dulski, Jarosław , Soto‐Beasley, Alexandra I. , Uitti, Ryan J. , Ross, Owen A. , Ross, Owen A , Dulski, Jaroslaw , Beasley, Alexandra I , Wszołek, Zbigniew K.

Mayo Clinic

Brain | July 14, 2023 | Volume: 146 | Issue: 12 | Pages: e125-e127

10.1093/brain/awad244 | PMID 37448355 Get It

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.